➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Merck
McKesson
Boehringer Ingelheim
Dow

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,383,876

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,383,876 protect, and when does it expire?

Patent 10,383,876 protects ALIQOPA and is included in one NDA.

This patent has fifty-two patent family members in forty-one countries.

Summary for Patent: 10,383,876
Title:Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Abstract: The present invention relates:--to 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo-[1,2-- c]quinazolin-5-yl]pyrimidine-5-carboxamide dihydrochloride salt of formula (II): or a tautomer, solvate or hydrate thereof;--to methods of preparing said dihydrochloride salt;--to said dihydrochloride salt for the treatment and/or prophylaxis of a disease;--to the use of said dihydrochloride salt for the preparation of a medicament for the treatment and/or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, more particularly for the treatment or prophylaxis of a cancer, particularly lung cancer, in particular non-small cell lung carcinoma, colorectal cancer, melanoma, pancreatic cancer, hepatocyte carcinoma, pancreatic cancer, hepatocyte carcinoma or breast cancer;--to a pharmaceutical composition comprising said dihydrochloride salt; and--to a pharmaceutical combination comprising said dihydrochloride salt in combination with one or more further pharmaceutical agents. ##STR00001##
Inventor(s): Peters; Jan-Georg (Solingen, DE), Militzer; Hans-Christian (Odenthal, DE), Muller; Hartwig (Velbert, DE)
Assignee: BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)
Application Number:14/009,599
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound; Delivery;

Drugs Protected by US Patent 10,383,876

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Healthcare ALIQOPA copanlisib dihydrochloride POWDER;INTRAVENOUS 209936-001 Sep 14, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,383,876

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11161111Apr 5, 2011
PCT Information
PCT FiledMarch 29, 2012PCT Application Number:PCT/EP2012/055600
PCT Publication Date:October 11, 2012PCT Publication Number: WO2012/136553

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Mallinckrodt
Merck
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.